ArticleNature and science of sleep2023
Association Between Metabolic-Associated Fatty Liver Disease and Obstructive Sleep Apnea: A Cross-Sectional Study.
Article in Nature and science of sleep, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease.Hepatology international · 2025Guideline
- Hypoxia in MASLD: a spatial determinant of the pathogenesis.Trends in molecular medicine · 2026Review
- Metabolic dysfunction-associated steatotic liver disease and obstructive sleep apnea: A cohort analysis of prevalence and hepatic outcomes.World journal of gastrointestinal pharmacology and therapeutics · 2026Article
- Association between metabolic dysfunction-associated steatotic liver disease and obstructive sleep apnea: a nationwide retrospective cohort study.Scientific reports · 2026Article
- Pathophysiology of depression and anxiety in metabolic dysfunction-associated steatotic liver disease.World journal of gastrointestinal pathophysiology · 2025Review
- Revisiting the association between metabolic dysfunction-associated steatotic liver disease and sleep: Moving from correlation to causation.World journal of gastroenterology · 2025Article
- Differential Risk of Obstructive Sleep Apnea in Alcoholic Versus Non-Alcoholic Fatty Liver Disease: A Propensity-Matched Cohort Study.Medicina (Kaunas, Lithuania) · 2025Article
- Metabolic-dysfunction associated steatotic liver disease and atrial fibrillation: A review of pathogenesis.World journal of cardiology · 2025Review
- Nephrological, Pulmonary, and Dermatological Complications in the Context of MAFLD/NAFLD: A Narrative Review.Metabolites · 2025Review
- MAFLD as part of systemic metabolic dysregulation.Hepatology international · 2024Review
- Association between hemoglobin and non-alcoholic fatty liver disease (NAFLD) in United States adults: Results from NHANES 2017-2020.Preventive medicine reports · 2024Article
- Intermittent hypoxia induces hepatic senescence through promoting oxidative stress in a mouse model.Sleep & breathing = Schlaf & Atmung · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Emerging evidence has revealed that obstructive sleep apnea (OSA) is an independent risk factor for the development of a variety of adverse metabolic disease states. In this study, we evaluated the association between OSA severity and metabolic dysfunction-associated fatty liver disease (MAFLD) among Asian populations. Materials and Methods: This was a cross-sectional, single-center study. The study cohort consisted of patients undergoing polysomnography and abdominal ultrasonography. Logistic regression analysis was used to evaluate the independent risk factors of MAFLD in patients with OSA. Results: A total of 1065 patients (277 non-MAFLD and 788 MAFLD) were included in the study. The prevalence of MAFLD in non-OSA, mild-moderate OSA, and severe OSA patients was 58.16%, 72.41%, and 78.0%, respectively ( Conclusion: OSA-associated chronic intermittent hypoxia was independently associated with the risk of MAFLD, especially in OSA patients with a BMI ≥ 23 kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.